Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (291-300 of 331) with videos related to

Pageof 34
Sort By:
Multiple Sclerosis and Related Disorders|September 10, 2020
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension studyAaron E Miller, Tomas P Olsson, Jerry S Wolinsky, et al.
Neurology|February 12, 2016
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO studyPaul O'Connor, Giancarlo Comi, Mark S Freedman, et al.
Journal of Virology|February 1, 1997
Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognitionC C Wilson, S A Kalams, B M Wilkes, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Neurology|March 21, 2002
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]K P Johnson, B R Brooks, J A Cohen, et al.
Neurology|March 21, 2002
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995K P Johnson, B R Brooks, J A Cohen, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Pageof 34

Showing results (291-300 of 331) with videos related to

Sort By:
Pageof 34
Multiple Sclerosis and Related Disorders|September 10, 2020
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension studyAaron E Miller, Tomas P Olsson, Jerry S Wolinsky, et al.
Neurology|February 12, 2016
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO studyPaul O'Connor, Giancarlo Comi, Mark S Freedman, et al.
Journal of Virology|February 1, 1997
Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognitionC C Wilson, S A Kalams, B M Wilkes, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Neurology|March 21, 2002
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]K P Johnson, B R Brooks, J A Cohen, et al.
Neurology|March 21, 2002
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995K P Johnson, B R Brooks, J A Cohen, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Pageof 34